Skip to content

Vagal Nerve Stimulation in mTBI

Non-Invasive Vagal Nerve Stimulation in Veterans With Mild Traumatic Brain Injury (mTBI)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04437498
Acronym
VNS mTBI
Enrollment
100
Registered
2020-06-18
Start date
2021-02-25
Completion date
2026-12-10
Last updated
2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mTBI, PTSD

Keywords

vagus nerve, stress disorders, posttraumatic, traumatic brain injury, memory, hippocampus, emission tomography

Brief summary

Mild traumatic brain injury (mTBI) and posttraumatic stress disorder (PTSD) are important conditions for the Veterans Administration (VA) that frequently occur together in combat Veterans from the conflicts in Afghanistan and Iraq. In many Veterans these become chronic, raising the risk the burden of neurotrauma can worsen over time. This study will examine a new intervention called non-invasive Vagal Nerve Stimulation (nVNS) and its effects on memory and symptoms of PTSD and mTBI as well as brain and physiology in Veterans with mTBI and PTSD.

Detailed description

This projects will assess the effects of non-invasive Vagal Nerve Stimulation (nVNS) on neurobiology and cognition in combat Veterans with mild Traumatic Brain Injury (mTBI) and co-morbid posttraumatic stress disorder (PTSD) during the performance of stressful tasks (traumatic scripts, mental arithmetic) and verbal declarative memory tasks using measurement of memory performance, peripheral inflammatory markers in blood (IL6) and cardiovascular responses using wearable gated sensing devices and electro- and seismocardiography, as well as brain response (anterior cingulate, hippocampus) measured with High Resolution Positron Emission Tomography (HR-PET) and radiolabelled water (15O\[H2O\]). The investigators hypothesize that nVNS but not sham control will result in enhanced memory, and hippocampal activation with memory encoding, and reduced cardiovascular, sympathetic, and inflammatory responses to stress. The investigators will also assess the effects of nVNS and sham on memory retention when applied to the encoding phase of a declarative memory learning task repeated daily over a four day period and on ratings of PTSD and pain in Veterans with mTBI and co-morbid PTSD and repeat assessments after three months of twice daily treatments.

Interventions

DEVICEsham stimulation

non invasive vagal nerve stimulation

DEVICEnVNS

active vns stimulation

Sponsors

VA Office of Research and Development
Lead SponsorFED
Atlanta VA Medical Center
CollaboratorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

code for active and sham devices kept by non study personnel.

Intervention model description

Veterans are randomized to double blind treatment with active non-invasive Vagal Nerve Stimulation (nVNS) or a sham control.

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* Veterans with mTBI and PTSD

Exclusion criteria

* amnesia for the inciting event lasted longer than 24 hours * Glasgow Coma Scale Score after 30 minutes was less than 13 * loss of consciousness more than 30 minutes * positive pregnancy test * meningitis or other neurological disorder other than mTBI * alcohol or substance abuse use disorder based on the SCID within the past 12 months * current or lifetime history of schizophrenia, schizoaffective disorder, bipolar disorder, anorexia nervosa or bulimia, based on the SCID * active suicidal ideation based on criteria outlined below * a history of serious medical or neurological illness, such as cardiovascular, gastrointestinal, hepatic, renal, neurologic or other systemic illness * active neuroleptic, opiate, or benzodiazepine treatment * structural abnormality on brain MRI or CT

Design outcomes

Primary

MeasureTime frameDescription
CAPSthree monthsThe Clinician Administered Posttraumatic Stress Disorder (PTSD) Scale (CAPS) is a measure of PTSD symptoms with a range of 0-80 and higher score indicating more severe PTSD symptoms. The investigators will compare change from baseline to post treatment with active vagal nerve stimulation (VNS) or sham stimulation twice daily.
insula10 minutesBlood flow in the insula is measured with positron emission tomography (PET) and radiolabelled water during the performance of stress tasks. The investigators will compare blood flow in the insula to whole brain blood flow ratio during stress tasks (listening to personalized traumatic scripts) versus control tasks in the VNS versus sham groups with hypothesis of blocked insula blood flow with VNS
HVLT-R % retentionbaseline versus three monthsThe Hopkins Verbal Learning Test-Revised (HVLT-R) is a test of declarative memory learning that involves the learning of 12 nouns, four from each of three semantic categories, learned over three learning trials, followed 20 minutes later by a delayed free recall trial and recognition trial composed of 24 words with 12 false positives. The percent (%) retention is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3. HLVT-R % retention has a range of 0-100 with 100 being best and 0 worst performance. Baseline and three months post treatment paired with sham or active stimulation are compared.
Change in IL6 Concentration in Blood with StressBaseline to 120 minutes after stressInterleukin-6 (IL6) response to stress paired with active or sham stimulation. IL6 is an inflammatory biomarker measured in blood. The investigators will compare IL6 response to stress in VNS versus sham treated groups.
hippocampal activation10 minutesBlood flow in the hippocampus is measured with positron emission tomography (PET) and radiolabelled water during the performance of declarative memory tasks. The investigators will compare blood flow in the hippocampus to whole brain blood flow ratio during memory tasks versus control tasks in the VNS versus sham groups with hypothesis of increased hippocampal blood flow with VNS

Secondary

MeasureTime frameDescription
PPG amplitudeChange from baseline to 5 seconds after the termination of stimulation paired with stressPhotoplethysmography (PPG) amplitude is a measure of peripheral vasoconstriction which is a marker of sympathetic response to stress with active or sham. PPG amplitude is the diameter of the blood vessel in the finger, the investigators will measure change from baseline to post active vagal nerve stimulation versus sham stimulation with stress.

Countries

United States

Contacts

CONTACTDoug J Bremner, MD
James.Bremner@va.gov(404) 712-9569
CONTACTAnna Woodbury, MD
Anna.Woodbury@va.gov(404) 321-6111
PRINCIPAL_INVESTIGATORDoug J Bremner, MD

Atlanta VA Medical and Rehab Center, Decatur, GA

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 21, 2026